Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs

Friday, 28th January, 2022
11:00h - 12:30h (UTC)

Richard S Finn, MD

Gastrointestinal Medical Oncologist

Geffen School of Medicine at UCLA in the Department of Medicine Division of Hematology/Oncology, USA

United States

More information

Mohamed Bouattour, MD

Gastroenterologist, Hepatologist and Medical Oncologist

The University Beaujon Hospital Clichy, Beaujon, France

France

More information

James J. Harding, MD

Gastrointestinal Oncologist

Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, USA

United States

More information

Dr. Su Pin Choo

Medical Oncologist

Curie Oncology and National Cancer Center in Singapore

Singapore

More information

The HCC Virtual Experts Knowledge share will address “Appropriate selection of patients for 1^st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. The Faculty includes Dr Mohamed Bouattour (France) and Dr Su Pin Choo (Singapore) with presentations from Prof. Richard Finn, MD, (USA) and Dr. James Harding (USA)

The educational objectives for the meeting are:

Explore the patient-profile who could benefit from VEGFR-TKI monotherapy 1^st line in advanced or unresectable HCC
Interpret the real-world data and understand the implications for clinical practice
Understand the safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
A look into the future, the potential of combination therapies in the treatment of HCC